Evidence map›Paper›PMID 32350779›Full record

ArticleJournal of neuro-oncology2020

Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.

Siyu Shi, Joseph Abi Jaoube, Ruhi Kanwar, Michael C Jin, Alvaro Amorin, Vamsi Varanasi, Ella Eisinger, Reena Thomas, Justin M Moore

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Neurologic adverse events of cancer immunotherapy.Arquivos de neuro-psiquiatria · 2022
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Siyu ShiDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Joseph Abi JaoubeDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Ruhi KanwarDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Michael C JinDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Alvaro AmorinDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Vamsi VaranasiDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Ella EisingerDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Reena ThomasDepartment of Oncology, Stanford School of Medicine, Stanford, CA, USA.
Justin M MooreNeurosurgery Service, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA, 02215, USA. jmoore4@bidmc.harvard.edu.ORCID http://orcid.org/0000-0003-2385-6357
Stanford Medicine · USBeth Israel Deaconess Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePD-1 Immunotherapy is integral in treating multiple cancers, but has been associated with neurological adverse events (nAEs). Our study was aimed at identifying the clinical spectrum of nAEs associated with pembrolizumab and nivolumab.

methodsWe performed an IRB approved single-center retrospective cohort study on patients receiving either pembrolizumab or nivolumab. Patients that developed nAEs within 12 months of treatment were identified. Descriptive statistics were conducted, and differences between groups were analyzed by the Chi-square or t test method.

resultsIn total, 649 patients were identified. Seventeen patients (2.6%) developed nAEs. Eight of those were on pembrolizumab and nine were on nivolumab. Average age was 62.1 years. Ten were males and 7 were females. Most patients had melanoma (6, 35.3%). Patients who developed nAEs more frequently had intracranial lesions at initiation of anti PD-1 therapy compared to those who did not develop nAEs (76.5% vs 27.8%; p-value < 0.001). Fifteen patients (88.2%) permanently stopped PD-1 therapy. In 8 patients, treatment termination resolved symptoms attributed to immune checkpoint blockade. The majority of patients developed grade 3 or 4 nAEs (10 patients, 58.8%), and required hospitalization (11 patients, 64.7%). Eight patients died for nAEs referable causes.

conclusionPembrolizumab and nivolumab are associated with the development of nAEs associated with increased risk of permanent discontinuation of treatment, hospitalization, and death. Melanoma patients might be at a particularly high risk of such side effects. Future studies are still required to better assess which patients benefit most from such therapies, while minimizing the risk of complications.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalChildFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasmsNervous System DiseasesNivolumabRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsNivolumabpembrolizumabNeurological adverse eventsNivolumabPD-1inhibitorsPD-L1 inhibitorsPembrolizumab

Identifiers

PMID32350779
OpenAlexW3021010873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.